Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
Stay informed about BioCorRx Inc.'s developments in addiction treatment solutions, clinical trial progress, and business updates. The company's news flow typically includes announcements related to its Beat Addiction Recovery Program expansion, BICX104 clinical development milestones, LUCEMYRA commercial distribution activities, and financial performance updates.
Key areas of news coverage include regulatory submissions and approvals for the company's pharmaceutical development programs, particularly BICX104, the investigational long-acting naltrexone implant. Investors and industry observers monitor announcements regarding clinical trial enrollments, interim data releases, and completion milestones as BICX104 advances through the regulatory pathway toward potential FDA approval for opioid use disorder, alcohol use disorder, and methamphetamine use disorder.
Partnership announcements represent another significant category of BioCorRx news, as the company expands its network of treatment providers utilizing the Beat Addiction Recovery Program. Strategic collaborations with healthcare organizations, particularly those serving veteran populations and underserved communities, indicate program adoption trends and potential revenue growth opportunities.
Financing and grant awards also generate notable news items, especially federal research funding from agencies like the National Institute on Drug Abuse (NIDA). These grants support clinical development activities and validate the therapeutic potential of the company's product candidates. Financial results, including quarterly and annual earnings reports, provide insights into LUCEMYRA sales performance, Beat Addiction program licensing revenues, and the company's operational progress.
Additional news topics include presentations at medical and investor conferences, peer-reviewed publications of clinical data, manufacturing partnerships, intellectual property developments, and updates regarding expanded access programs that allow patients to receive investigational treatments prior to formal approval. Given the company's focus on addressing the opioid epidemic and substance use disorders, BioCorRx's activities may also intersect with broader public health policy discussions and addiction treatment initiatives.
BioCorRx Inc. (OTCQB: BICX) provided a business update for Q3 2021, highlighting progress in its FDA drug approval process for BICX104, an implantable pellet for opioid use disorder. The company secured approximately $3.5 million in non-dilutive funding from the National Institute on Drug Abuse (NIDA), aiding their FDA submission efforts. An agreement with IriSys LLC was expanded for manufacturing support. Additionally, BioCorRx filed patent applications in the U.S. and Russia for BICX104, furthering its intellectual property strategy.
BioCorRx Inc. (OTCQB: BICX) announced the filing of a patent application with the Russian Patent Office for a biodegradable naltrexone implant aimed at treating opioid use disorder (OUD). The application focuses on BICX104, an implantable pellet developed by BioCorRx Pharmaceuticals, the company's R&D subsidiary. CEO Lourdes Felix emphasized the company’s commitment to addressing the global opioid crisis, particularly in Russia, where drug use affects around 6% of the population. BioCorRx has received FDA clearance to start human trials for BICX104, funded significantly by the National Institute on Drug Abuse.
BioCorRx Inc. (OTCQB: BICX) will present at LD Micro’s 14th annual Main Event on October 12, 2021, at 1:30 PM PT in Los Angeles. CEO Lourdes Felix and Brady Granier will represent the company during the event, which aims to feature about 150 companies. The conference will be held from October 12 to 14, 2021, showcasing investor presentations and keynotes. BioCorRx specializes in innovative solutions for substance use disorders, including the Beat Addiction Recovery program and UnCraveRx® for weight loss.
BioCorRx Inc. (OTCQB: BICX) has filed a patent application for a biodegradable implant containing naltrexone, specifically targeting opioid use disorder (OUD) with its product BICX104. The FDA has cleared the company to begin human trials for this drug candidate. Funding for the project is significantly provided by a $3.5 million non-dilutive grant from the National Institute on Drug Abuse (NIDA). CEO Lourdes Felix expressed optimism about advancing BICX104 towards FDA approval as the company prepares for the first-in-human clinical trial.
Recro Pharma and BioCorRx have expanded their partnership through a new development and manufacturing agreement. Recro will provide analytical validation services and cGMP manufacturing of registrational batches of BICX104 to support its New Drug Application (NDA) filing with the FDA. This agreement builds on a prior Master Services Agreement and underscores BioCorRx's commitment to advancing its treatment for opioid use disorder. The project has significant backing from the National Institute on Drug Abuse, and human trials for BICX104 are set to begin soon.
BioCorRx Inc. (OTCQB: BICX) announced it has received a $3.5 million grant from the National Institute on Drug Abuse (NIDA) to commence a first-in-human clinical trial for BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder. This funding builds on a total of $5.7 million received for a prior phase. FDA clearance has been obtained to begin trials this year, which will evaluate the pellet's safety, longevity, and tolerability. The company underscores the significance of this milestone in advancing its product toward market availability.
BioCorRx Inc. (OTCQB: BICX) announced a significant milestone in its business update for Q2 2021. The company received FDA clearance to initiate human trials for BICX104, an implantable pellet designed for opioid use disorder. This trial aims to evaluate the safety, longevity, and tolerability of BICX104, with potential dual indications for both opioid and alcohol use disorders. Additionally, the firm expanded its Scientific Advisory Board with four new members to support the upcoming trials. The company emphasizes the urgent need for effective treatment amidst the ongoing drug overdose epidemic.
BioCorRx (OTCQB: BICX) announced the addition of four new members to its Scientific Advisory Board, increasing the total to seven. The new advisors, including Dr. Ashok Kumar, Michael Howcroft, Priya Jambhekar, and Dr. Jeff Witkin, bring extensive experience in drug development and regulatory affairs. Their expertise aims to support the advancement of BICX104, an implantable naltrexone pellet for opioid use disorder, as the company navigates urgent treatment needs exacerbated by the COVID-19 pandemic. CEO Lourdes Felix expressed optimism about their contributions to improving treatment programs.
BioCorRx Inc. (OTCQB: BICX) reported significant advancements as of May 18, 2021. The company received FDA clearance to initiate human trials for BICX104, a gradual release implantable pellet aimed at treating opioid use disorder. Aiming to commence trials later this year, BioCorRx is also focused on its Beat Addiction Recovery program, combining cognitive-behavioral therapy with medication-assisted treatment. This comes amid rising substance abuse challenges exacerbated by COVID-19.
BioCorRx (OTCQB: BICX) announced FDA clearance to proceed with human trials for BICX104, an implantable naltrexone pellet targeting Opioid Use Disorder (OUD). The clinical trial, set to begin later this year, follows an IND submission to the FDA and an earlier pre-IND meeting where a potential dual indication for OUD and Alcohol Use Disorder (AUD) was discussed. With over 81,000 drug overdose deaths reported in the U.S. during the past year, this development is positioned as a critical response to the ongoing opioid crisis.
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
